The age of precision medicine has already begun and inaction is not an option.
Improving healthcare requires a deeper understanding of the human body. Today’s patients are looking for bespoke healthcare and expect the best outcomes in disease prevention, diagnosis and treatment. So, how can Life Sciences and Healthcare companies scale up to gain a competitive edge in a market projected to reach USD134.82 billion in 2026 at a CAGR of 12.8%?
Embracing the emergence and maturation of new technologies, companies can tap into the individual uniqueness of a patient’s genetic makeup, behavior, culture, lifestyle and environment to gain a competitive edge in this growing market. Ready to delve deeper into a data-powered platform to achieve precision medicine at scale?
Our ebook demonstrates how an integrated digital platform can unlock precision medicine's full potential to deliver personalized health solutions and better patient outcomes with agility and speed.
According to a Deloitte report, data is the new currency of life sciences and healthcare innovation. Exploiting new tools to extract meaning from large volumes of information will drive real change in clinical practice and biomanufacturing. Data science can help companies:
Deliver more ‘right first-time' results at a lower cost
Produce highly customized, products and services
Maintain economy of scale and time-to-market
Guided by real-time insights, healthcare providers can make the right decisions from end to end. For example, in silico trials transform large volumes of data at scale to improve success probabilities in innovative trial designs.
Continuous monitoring and data intelligence will enable us to contextualize healthcare decisions and tailor-make patient treatments that capture the uniqueness of each patient and track the subtleties of chronic conditions.
Healthcare providers can utilize advanced digital platform technologies to make the pursuit of precision medicine possible, practical, faster and more cost-effective. These technologies include:
As a complete dynamic “living” model of the human body and its constituent systems, the virtual twin enables new understanding and approaches to health diagnosis, prognosis, treatments and anticipation of future conditions. In pharmaceutical operations, a virtual twin helps healthcare providers quickly identify potential therapy candidates. For example, genetic engineering provides the basis for novel cell and gene therapy by identifying tumor genetic mutations.
Predictive analytics can be leveraged to find factors and risks associated with a therapeutic intervention or predict which patient would respond best to a treatment. This reduces the time needed to develop and optimize the processes and hardware to manufacture highly-customized novel therapies for smaller patient populations. Discover how biopharmaceutical manufacturers successfully managed all process related constraints in this whitepaper when dealing with rigorous regulatory requirements for record keeping, data integrity, sign-offs, quality and stringent traceability.
With a modular, predictive and digitalized approach, companies can improve outcomes in personalized prosthetics. Advances in realistic simulation and virtual modeling of the human limb are expediting key attributes of form, fit and comfort to be incorporated in fabricated prototypes.
By leveraging virtual 3D universes to simulate, optimize and rework processes before applying them in the real world, let’s see how these digital platform technologies can help companies deliver personalized medicine and healthcare to patients.
As an integrated scientific and business platform, the 3DEXPERIENCE® platform digitally connects and aligns the patient and healthcare ecosystem for easy access to information, enabling quicker and data-driven decision-making.
“Evolving healthcare introduces complexity in processes. Scientific breakthroughs and affordability will be instrumental in the wider use of precision medicine. To remain competitive, companies must shift to new approaches that are customizable, highly flexible and resource-efficient,” said Claire Biot, Life Sciences and Healthcare Industry Vice President at Dassault Systèmes.
"We will see a wave of mainstream personalized medicine in the next 10 to 20 years. The 3DEXPERIENCE platform – with virtual twin technology at its core – provides companies with the agility and modularity to get there faster and be future-ready," she added.
Learn more about how our Industry Solutions can help you achieve your professional ambitions and business objectives.